// App-Quantinova.ai

P972 : INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN'S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS

Researchers

Presenter

  • Katja Weisel

Principal Investigators

  • Ajai Chari

  • Saad Z Usmani

  • Hartmut Goldschmidt

  • Maria-Victoria Mateos

  • Keqin Qi

  • Anil Londhe

  • Sandhya Nair

  • Xiwu Lin

  • Lixia Pei

  • Eric Ammann

  • Rachel Kobos

  • Jennifer Smit

  • Trilok Parekh

  • Mary Slavcev

  • Phillippe Moreau

Medical Centers

  • CIC,University Hospital of Salamanca/IBSAL,Salamanca,Spagna

  • Development,Titusville,Verenigde Staten

  • Development,Bridgewater, NJ,Stati Uniti

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Development, LLC,Spring House, PA,Vereinigte Staaten

  • Development,Bridgewater,Estados Unidos

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Janssen Global Services,Rar

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Memorial Sloan Kettering Cancer Center,New York ,États-unis

  • Janssen Global Services,Raritan,Vereinigte Staaten

  • Memorial Sloan Kettering Cancer Center,New York,Vereinigte Staaten

  • Development,Bridgewater,United States

  • Janssen Global Services,Horsham,Stati Uniti

  • Development,Raritan, NJ,Vereinigte Staaten

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • University Hospital Heidelberg and Nation

  • Development, LLC,Titusville, NJ,Stati Uniti

  • University Medical Center Utrecht,

  • Dev

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • University Hospital Heidelberg and National Center of Tumor Diseases,Heidelberg,Deutschland

  • Development, IHI RWE,Titusville, NJ,United States

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Janssen Global Services, Raritan, NJ, United States

  • Janssen Global Services,Rar

  • Hematology Clinic, University Hospital Hôtel-Dieu,Nantes,Francia

  • Janssen Global Services,Horsham,United States

  • Development,Bridgewater, NJ,États-unis

  • Development, LLC,Titusville, NJ,Stati Uniti

  • Development,Raritan, NJ,Vereinigte Staaten

  • Development,Raritan,United States

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Janssen Research &amp

  • Development, LLC,Spring House, PA,Vereinigte Staaten

  • Development, LLC,Raritan, NJ,États-unis

  • CIC,University Hospital of Salamanca/IBSAL,Salamanca,Spagna

  • Development,Titusville, NJ,Vereinigte Staaten

  • Development,Bridgewater,Verenigde Staten

  • Mount Sinai Schoo

  • Memorial Sloan Kettering Cancer Center,New York,Vereinigte Staaten

  • Janssen Rese

  • Janssen Global Services,Raritan,Estados Unidos

  • Jansse

  • CIC,University Hospital of Salamanca/IBSAL,Salamanca,Spagna

  • Hematology Biology, University Hospital Hotel Dieu, Nantes, France

  • Development,Raritan,Stati Uniti

  • Development,Spring House, PA,Stati Uniti

  • Mount Sinai School of Medicine,New York, NY,Estados Unidos

  • The Mount Sinai School of Medicine, New York, United States

  • Development, LLC,Spring House, PA,Estados Unidos

  • Janssen Global Services,Raritan,Estados Unidos

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • CIC,University Hospital of Salamanca/IBSAL,Salamanca,Spagna

  • Development,Raritan,Estados Unidos

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Mount Sinai School of Medicine,New York,États-unis

  • Janssen Global Services,Horsham,United States

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Hematology Clinic, University Hospital Hôtel-Dieu,Nantes,Francia

  • Hematology Clinic, University Hospital Hôtel-Dieu,Nantes,Francia

  • University Hospital Heidelberg and National Center of Tumor Diseases,Heidelberg,Germania

  • Department of Neurology, University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany

  • Development, LLC,Spring House,United States

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Mount Sinai School of Medicine,New York,Vereinigte Staaten

  • Janssen Global Services,Raritan,Vereinigte Staaten

  • Development,Titusville,Estados Unidos

  • CIC,University Hospital of Salamanca/IBSAL,Salamanca,Spagna

  • Janssen Global Services,Horsham, PA,Estados Unidos

  • Janssen Global Services,Horsham,United States

  • Development,Bridgewater,Verenigde Staten

  • Memorial Sloan Kettering, NY

  • CIC,University Hospital of Salamanca/IBSAL,Salamanca,Spagna

  • Mount Sinai School of Medicine,New York,États-unis

  • Janssen Global Services,Raritan,Estados Unidos

  • Janssen Global Services,Horsham,Stati Uniti

  • Mount Sinai School of Medicine,New York,Vereinigte Staaten

  • Development,Spring House,États-unis

  • University Hospital Heidelberg and National Center of Tumor Diseases,Heidelberg,Deutschland

Locations

  • Germany

  • United States

  • South Africa

  • Mexico

  • Spain

  • Belgium

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Extramedullary plasmacytoma

  • Plasmacytoma

Biomarkers

  • N/A

Drug/Treatment

  • daratumumab Intravenous

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • I/II

Study Id's

  • NCT04557098

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved